» Articles » PMID: 17693625

ApoA-I Cleaved by Transthyretin Has Reduced Ability to Promote Cholesterol Efflux and Increased Amyloidogenicity

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2007 Aug 19
PMID 17693625
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

A fraction of plasma transthyretin (TTR) circulates in HDL through binding to apolipoprotein A-I (apoA-I). Moreover, TTR is able to cleave the C terminus of lipid-free apoA-I. In this study, we addressed the relevance of apoA-I cleavage by TTR in lipoprotein metabolism and in the formation of apoA-I amyloid fibrils. We determined that TTR may also cleave lipidated apoA-I, with cleavage being more effective in the lipid-poor prebeta-HDL subpopulation. Upon TTR cleavage, discoidal HDL particles displayed a reduced capacity to promote cholesterol efflux from cholesterol-loaded THP-1 macrophages. In similar assays, TTR-containing HDL from mice expressing human TTR in a TTR knockout background had a decreased ability to perform reverse cholesterol transport compared with similar particles from TTR knockout mice, reinforcing the notion that cleavage by TTR reduces the ability of apoA-I to promote cholesterol efflux. As amyloid deposits composed of N-terminal apoA-I fragments are common in the atherosclerotic intima, we assessed the impact of TTR cleavage on apoA-I aggregation and fibrillar growth. We determined that TTR-cleaved apoA-I has a high propensity to form aggregated particles and that it formed fibrils faster than full-length apoA-I, as assessed by electron microscopy. Our results show that apoA-I cleavage by TTR may affect HDL biology and the development of atherosclerosis by reducing cholesterol efflux and increasing the apoA-I amyloidogenic potential.

Citing Articles

A review of cutting-edge biomarkers for diagnosing coronary artery disease.

Azami P, Mohammadzadeh S, Seirafi S, Razeghian-Jahromi I Medicine (Baltimore). 2025; 104(4):e41377.

PMID: 39854741 PMC: 11771658. DOI: 10.1097/MD.0000000000041377.


Tetrameric Transthyretin as a Protective Factor Against Alzheimer's Disease.

Corino C, Aimo A, Luigetti M, Ciccone L, Ferrari Chen Y, Panichella G Mol Neurobiol. 2024; 62(3):2945-2954.

PMID: 39192044 PMC: 11790689. DOI: 10.1007/s12035-024-04442-8.


Synergistic Anti-Inflammatory Activity of Lipid-Free Apolipoprotein (apo) A-I and CIGB-258 in Acute-Phase Zebrafish via Stabilization of the apoA-I Structure to Enhance Anti-Glycation and Antioxidant Activities.

Cho K, Bahuguna A, Lee Y, Lee S, Dominguez-Horta M, Martinez-Donato G Int J Mol Sci. 2024; 25(10).

PMID: 38791598 PMC: 11121824. DOI: 10.3390/ijms25105560.


Proteomics analysis of coronary atherosclerotic heart disease with different Traditional Chinese Medicine syndrome types before and after percutaneous coronary intervention.

Zhibo W, Ying L, Daoping W, Bo M, Lan M, Junguo R J Tradit Chin Med. 2024; 44(3):554-563.

PMID: 38767640 PMC: 11077157. DOI: 10.19852/j.cnki.jtcm.20240408.001.


Lipoproteins and Calcific Aortic Valve Disease: Hardening Evidence?.

OBrien K Arterioscler Thromb Vasc Biol. 2022; 42(11):1321-1323.

PMID: 36134565 PMC: 9613592. DOI: 10.1161/ATVBAHA.122.318310.